Stay updated with breaking news from Alan Stitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Oxurion NV, OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting
Press release content from Globe Newswire. The AP news staff was not involved in its creation. OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting Oxurion NVApril 30, 2021 GMT Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 20...
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD 04/07/2021 | 11:45am EDT Send by mail : Message : Required fields Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for ...
Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD & Corporate Communications wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) EU Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com (mailto:thrombogenics@citigatedewerogerson.com) US chris.brinzey@westwicke.com (mailto:chris.brinzey@westwicke.com) About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of ... Oxurion NVApril 7, 2021 GMT Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, a...